Conventional and molecular screening (fecal testing) in colorectal cancer;Konventionelles und molekulares screening (stuhltests)

Internist

Volumn 44, Issue 3, 2003, Pages 287-293

  Pox, C ^a   Schulmann, K ^a   Schmiegel, W ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER SCREENING; COLORECTAL CANCER; DIAGNOSTIC PROCEDURE; ENDOSCOPY; FECES ANALYSIS; HUMAN; MOLECULAR BIOLOGY; OCCULT BLOOD TEST; PATIENT COMPLIANCE; REVIEW;

EID: 0037353959     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-002-0829-9     Document Type: Review

References (45)

1. Doran J, Hardcastle JD (1983) Patterns of bleeding in colorectal cancer - the effect of aspirin. Implications for faecal occult blood testing. Br J Surg 69: 711-713
2. Ahlquist DA, McGill DB, Fleming JL et al. (1989) Patterns of occult bleeding in asymptomatic colorectal cancer. Cancer 63: 1826-1830
3. Macrae FA, St. John DJ (1982) Relationship between patterns of bleeding and hemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology 82: 891-898
4. Greegor DH (1971) Occult blood testing for detection of asymptomatic colon cancer. Cancer 28: 131-134
5. Schmiegel W, Adler G, Frühmorgen P et al. (2000) Kolorektales Karzinom: Prävention und Früherkennung in der asynmptomatischen Bevölkerung - Vorsorge bei Risikopatienten - Endoskopische Diagnostik,Therapie und Nachsorge von Polypen und Karzinomen. Z Gastroenterol 38: 49-76
6. Winawer SJ, Fletcher RH, Miller L et al. (1997) Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 112: 594-642
7. St. John DJ, McDermott FT, Hopper JL, Debney EA, Johnson WR, Hughes ES (1993) Cancer risk in relatives of patients with common colorectal cancer. Ann Intern Med 118: 785-790
8. Lieberman DA, Weiss DG (2001) One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 345: 555-560
9. Mandel JS, Bond JH, Church TR et al. (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328: 1365-1371
10. Ransohoff DF, Sandler RS (2002) Screening for colorectal cancer. N Engl J Med 346: 40-44
11. Hardcastle JD, Chamberlain JO, Robinson MH et al. (1996) Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348: 1472-1477
12. Kewenter J, Bjork S, Haglind E, Smith L, Svanvik J, Ahren C (1988) Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27.700 subjects. Cancer 62; 645-651
13. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Søndergaard O (1996) Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348: 1467-1471
14. Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C (1998) A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ 317: 559-565
15. Gabrielsson N, Granquist S, Nilsson B (1985) Guaiactests detection of occult faecal blood loss in patients with endoscopically verified colonic polyps. Scand J Gastroenterol 20: 978-982
16. Crwoley ML, Freeman LD, Mottet MD et al. (1983) Sensitivity of guaiac-impregnated cards for the detection of colorectal neoplasia. J Clin Gastroenterol 5: 27-130
17. Selby JV, Friedman GD, Quesenberry CP (1993) Effect of fecal occult blood testing on mortality from colorectal cancer. Ann Intern Med 118: 1-6
18. Scholefield JH, Moss S, Sufi F, Mangham CM, Hardcastle JD (2002) Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut 50: 840-844
19. Jorgensen OD, Kronborg O, Fenger C (2002) A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 50: 29-32
20. Mandel JS, Church TR, Ederer F, Bond JH (1999) Colorectal cancer mortality: Effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 91: 434-437
21. Mandel JS, Church TR, Bond JH et al. (2000) The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 343: 1603-1607
22. Ransohoff DF, Lang CA (1997) Screening for colorectal cancer with the fetal occult blood test: a background paper. Ann Intern Med 126: 811-822
23. Allison JE, Tekawa IS, Ransom LJ, Adrain AL (1996) A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 334: 155-159
24. Sonnenberg A, Delcó F, Inadomi JM (2000) Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 133: 573-584
25. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM (2000) Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 284: 1954-1961
26. Vatn MH, Stalsbert H (1982) The prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer 49: 819-825
27. Steele GD (1994) The national cancer data base report on colorectal cancer. Cancer 74: 1979-1989
28. Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87: 159-170
29. Bos JL (1989) Ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689
30. Boland CR, Sato J, Appelman HD, Bresalier RS, Feinberg AP (1995) Microallelotyping defines the sequence and tempo of allelic losses at tumour suppressor gene loci during colorectal cancer progression. Nat Med 1: 902-909
31. Vogelstein B, Fearon ER, Hamilton SR et al. (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532
32. Fearon ER, Cho KR, Nigro JM et al. (1990) Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247: 49-56
33. Eppert K, Scherer SW, Ozcelik H et al. (1996) MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86: 543-552
34. Hahn SA, Schutte M, Hoque AT et al. (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350-353
35. Aaltonen LA, Peltomäki P, Mecklin JP et al. (1994) Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 54: 1645-1648
36. Sidransky D, Tokino T, Hamilton SR et al.(1992) Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 256: 102-105
37. Hasegawa Y, Takeda S, Ichii S et al. (1995) Detection of K-ras mutations in DNAs isolated from feces of patients with colorectal tumors by mutant-allele-specific amplification (MASA). Oncogene 10: 1441-1445
38. Smith-Ravin J, England J,Talbot IC, Bodmer W (1995) Detection of c-Ki-ras mutations in faecal samples from sporadic colorectal cancer patients. Gut 36: 81-86
39. Nollau P, Moser C, Weinland G, Wagener C (1996) Detection of K-ras mutations in stools of patients with colorectal cancer by mutant-enriched PCR. Int J Cancer 66: 332-336
40. Ratto C, Flamini G, Sofo L et al. (1996) Detection of oncogene mutation from neoplastic colonic cells exfoliated in feces. Dis Colon Rectum 39: 1238-1244
41. Villa E, Dugani A, Rebecchi AM et al. (1996) Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool. Gastroenterology 110: 1346-1353
42. Eguchi S, Kohara N, Komuta K, Kanematsu T (1996) Mutations of the p53 gene in the stool of patients with resectable colorectal cancer. Cancer 77: 1707-1710
43. Traverso G, Shuber A, Levin B et al. (2002) Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 346: 311-320
44. Ahlquist DA, Skoletsky JF, Soynton KA et al. (2000) Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 119: 1219-1227
45. Dong SM, Traverso G, Johnson C et al. (2001) Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 93: 858-865